Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma.

A reduced dose of lenalidomide can be an important factor for treatment continuation, since systemic AL amyloidosis patients are often intolerant to lenalidomide over 15 mg/day.13 One patient without haematological response at 6 months from DRd treatment had chromosome 1q21 amplification. Approximately 12%-15% of multiple myeloma (MM) patients develop systemic light chain amyloidosis (AL amyloidosis) during the clinical course.1 Treatment with daratumumab, cyclophosphamide, bortezomib and dexamethasone is becoming a standard of care for systemic AL amyloidosis patients according to the recently published phase-3 ANDROMEDA trial.2 However, patients with coexisting MM have been excluded from the trial. [Extracted from the article]